<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130999</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VEC-162-4101</org_study_id>
    <nct_id>NCT02130999</nct_id>
  </id_info>
  <brief_title>Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)</brief_title>
  <official_title>A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hetlioz™ (tasimelteon) is used in the treatment of Non-24-Hour-Sleep-Wake Disorder (Non-24).
      Non-24 is very common in people who are totally blind because light can not reset their body
      clock. This causes the internal sleep-wake cycle to be out of sync with the 24-hour
      day-night. Non-24 is a serious, chronic circadian rhythm disorder in the blind that causes
      nighttime sleep problems and a wide range of daytime difficulties, including an overwhelming
      urge to nap.

      Tasimelteon will be given in two ways; orally (by mouth) as a 20 mg capsule and intravenously
      (I.V.) by infusion through a catheter (not an injection) into a vein. The oral administration
      is approved by the FDA. The I.V. administration is considered investigational as it has not
      been approved by the FDA. This will be the first time tasimelteon will be given to humans by
      intravenous (I.V.) injection.

      The purposes of this research study are to:

        -  assess how quickly a single 20 mg oral dose of tasimelteon is absorbed into the body;

        -  evaluate the single-dose pharmacokinetics of tasimelteon after a single 20 mg oral dose
           and after a single 2 mg I.V. dose;

        -  evaluate the single-dose pharmacokinetics of tasimelteon metabolites after a single 20
           mg oral dose and after a single 2 mg I.V. dose;

        -  evaluate the safety and tolerability of a single 20 mg oral dose of tasimelteon; and

        -  evaluate the safety and tolerability of a single 2 mg I.V. dose of tasimelteon.

      Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and
      eventually eliminated by the body. Pharmacokinetics is what the body does to the drug. Blood
      samples will be taken throughout the study for PK analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Cmax of tasimelteon will be compared when given orally or administered as an I.V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours pos-dose</time_frame>
    <description>T1/2 of tasimelteon will be compared when given orally or administered as an I.V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>CL of tasimelteon will be compared when given orally or administered as an I.V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>The mean +/- SD for the Cmax of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(Inf) of Tasimelteon's Metabolites After a Single Oral and I.V. Dose</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>The mean +/- SD for the AUC(inf) of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon</measure>
    <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From Baseline to End of Study; Day 5 (± 2 days).</time_frame>
    <description>Number of participants with treatment-emergent adverse event per treatment arm and overall.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.</measure>
    <time_frame>Baseline to End of Study Day 5 (± 2 days).</time_frame>
    <description>Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-24-Hour-Sleep-Wake Disorder</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of tasimelteon 20 mg on Day 1
Single I.V. dose of tasimelteon 2 mg on Day 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single I.V. dose of tasimelteon 2 mg on Day 1
Single oral dose of tasimelteon 20 mg on Day 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon 20 mg capsule</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <other_name>Hetlioz™ 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon 2 mg I.V.</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ages 18 - 55 years, inclusive;

          2. Non-smokers [abstinence from smoking for at least 6 months before the screening visit]
             and test negative for cotinine at screening and baseline;

          3. Subjects with Body Mass Index (BMI) of ≥18 and ≤25 kg/m2 (BMI = weight (kg)/ [height
             (m)]2);

          4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months
             before screening or subject is postmenopausal, without menses for 6 months before
             screening), or females of child-bearing potential using an acceptable method of birth
             control for a period of 35 days before the first dosing, and females must have a
             negative pregnancy test at the screening and baseline visits; Note 1: Acceptable
             methods of birth control include any one of the following: abstinence, vasectomized
             sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants,
             patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded
             coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam

          5. Vital signs (after 3 minutes resting in a semi-supine position) which are within the
             ranges shown below:

               1. Body temperature between 35.0-37.5 °C;

               2. Systolic blood pressure between 90-150 mmHg;

               3. Diastolic blood pressure between 50-95 mmHg;

               4. Pulse rate between 50-100 bpm.

          6. Ability and acceptance to provide written informed consent;

          7. Willing and able to comply with study requirements and restrictions;

          8. Subjects must be in good health as determined by past medical history, physical
             examination, electrocardiogram, clinical laboratory tests and urinalysis;

        Exclusion Criteria:

          1. History of recent (within six months) drug or alcohol abuse as defined in DSM-V,
             Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated
             by the laboratory assays conducted during the Screening Visit or at Baseline;

          2. Any major surgery within three months of the first Baseline visit or any minor surgery
             within one month;

          3. History or current evidence of cardiovascular, hepatic, hematopoietic, renal,
             gastrointestinal or metabolic dysfunction or psychiatric disease judged by the
             Investigator to be clinically significant;

          4. Subjects who are currently considered a suicide risk, any subject who has ever made a
             suicide attempt, or those who are currently demonstrating active (within the past 6
             months) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale
             (C-SSRS);

          5. Any condition requiring the regular use of medication except those listed in Section
             8.2;

          6. Exposure to any investigational drug, including placebo, within 30 days or 5
             half-lives (whichever is longer) of baseline

          7. Exposure (within 2 weeks of Day -1) to any over-the-counter medications including
             melatonin, dietary supplements and/or herbal remedies, except those listed on Section
             8.2;

          8. Treatment with any drug known to cause major organ system toxicity (e.g.,
             chloramphenicol or tamoxifen) during the 60 days preceding the Screening visit;

          9. History of intolerance and/or hypersensitivity to tasimelteon, and/or drugs similar to
             tasimelteon including melatonin;

         10. Donation or loss of 400 mL or more of blood within one month prior to the Baseline
             Visit;

         11. Significant illness within the two weeks prior to Baseline;

         12. Pregnant or lactating females;

         13. History of porphyria or liver disease and/or positive for one or more of the following
             serological results:

               1. A positive hepatitis C antibody test (anti-HCV)

               2. A positive hepatitis B surface antigen (HBsAg)

               3. A positive HIV test result

         14. Use of any food or beverage containing grapefruit or grapefruit juice, apple or orange
             juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress,
             collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats for
             at least 2 weeks before the Baseline Visit until the end of the study;

         15. Inability to be venipunctured and/or tolerate venous access;

         16. Previous participation in a BMS-214778, VEC-162, or tasimelteon study;

         17. Subjects who are unable to read or speak English;

         18. Any other sound medical reason as determined by the clinical Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-24</keyword>
  <keyword>absolute bioavailability</keyword>
  <keyword>tasimelteon</keyword>
  <keyword>Hetlioz™</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence A</title>
          <description>Single oral dose of tasimelteon 20 mg on Day 1
Single I.V. dose of tasimelteon 2 mg on Day 6
tasimelteon 20 mg capsule
tasimelteon 2 mg I.V.</description>
        </group>
        <group group_id="P2">
          <title>Sequence B</title>
          <description>Single I.V. dose of tasimelteon 2 mg on Day 1
Single oral dose of tasimelteon 20 mg on Day 6
tasimelteon 20 mg capsule
tasimelteon 2 mg I.V.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Baseline Participants</title>
          <description>14 subjects total participated in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>(kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>(kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>(cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg</title>
        <description>The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absolute Bioavailability</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg</title>
          <description>The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.</description>
          <units>Geometric Mean Ratio (%)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="26.9" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
        <description>Cmax of tasimelteon will be compared when given orally or administered as an I.V.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
          <description>Cmax of tasimelteon will be compared when given orally or administered as an I.V.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" spread="189"/>
                    <measurement group_id="O2" value="82.2" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
        <description>AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
          <description>AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.</description>
          <units>(h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358" spread="271"/>
                    <measurement group_id="O2" value="71.6" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
        <description>T1/2 of tasimelteon will be compared when given orally or administered as an I.V.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours pos-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
          <description>T1/2 of tasimelteon will be compared when given orally or administered as an I.V.</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.23"/>
                    <measurement group_id="O2" value="1.02" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
        <description>CL of tasimelteon will be compared when given orally or administered as an I.V.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.</title>
          <description>CL of tasimelteon will be compared when given orally or administered as an I.V.</description>
          <units>(mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2241" spread="3592"/>
                    <measurement group_id="O2" value="505" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon</title>
        <description>The mean +/- SD for the Cmax of tasimelteon’s metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon</title>
          <description>The mean +/- SD for the Cmax of tasimelteon’s metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303" spread="94.3"/>
                    <measurement group_id="O2" value="16.4" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="16.14"/>
                    <measurement group_id="O2" value="3.7" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="30.8"/>
                    <measurement group_id="O2" value="7.31" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" spread="105"/>
                    <measurement group_id="O2" value="29" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(Inf) of Tasimelteon’s Metabolites After a Single Oral and I.V. Dose</title>
        <description>The mean +/- SD for the AUC(inf) of tasimelteon’s metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Only 11 subjects could be analyzed for M11.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>AUC(Inf) of Tasimelteon’s Metabolites After a Single Oral and I.V. Dose</title>
          <description>The mean +/- SD for the AUC(inf) of tasimelteon’s metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon</description>
          <population>Only 11 subjects could be analyzed for M11.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" spread="139"/>
                    <measurement group_id="O2" value="30.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="43.7"/>
                    <measurement group_id="O2" value="12.2" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="619" spread="364"/>
                    <measurement group_id="O2" value="43.8" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" spread="152"/>
                    <measurement group_id="O2" value="38.2" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon</title>
        <description>Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.</description>
        <time_frame>pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral (20 mg)</title>
          </group>
          <group group_id="O2">
            <title>IV (2 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon</title>
          <description>Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.</description>
          <units>metabolite to parent AUC (inf) ratios</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.65"/>
                    <measurement group_id="O2" value="0.39" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.35"/>
                    <measurement group_id="O2" value="0.16" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.93"/>
                    <measurement group_id="O2" value="0.54" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.12"/>
                    <measurement group_id="O2" value="0.51" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants with treatment-emergent adverse event per treatment arm and overall.</description>
        <time_frame>From Baseline to End of Study; Day 5 (± 2 days).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon 20mg Oral</title>
          </group>
          <group group_id="O2">
            <title>Tasimelteon 2mg IV</title>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants with treatment-emergent adverse event per treatment arm and overall.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.</title>
        <description>Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.</description>
        <time_frame>Baseline to End of Study Day 5 (± 2 days).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon 20mg Oral</title>
          </group>
          <group group_id="O2">
            <title>Tasimelteon 2mg IV</title>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.</title>
          <description>Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tasimelteon 20mg Oral</title>
        </group>
        <group group_id="E2">
          <title>Tasimelteon 2mg IV</title>
        </group>
        <group group_id="E3">
          <title>All Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>sommolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melodie Armstrong, MD, MPH</name_or_title>
      <organization>Vince and Associates Clinical Research</organization>
      <phone>913-696-1601</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

